Sangamo reports updated data for gene therapy candidate ST-920
Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease. The ...
CRISPR technique helps reveal how bean genes could improve nitrogen fixation
Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...
sicklecellanemianews10h
SCD gene-editing therapy Casgevy now being offered at CHLA
With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.
Nanomachines loaded with wine ingredients overcome gene therapy challenges
Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...
STAT13h
The CRISPR companies are not OK
Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...
Inhibiting a gene provides a new weapon to fight treatment-resistant melanoma
The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant ...
emjreviews.com1d
Gene-Editing Therapy for Sickle Cell Disease Approved by NHS
Exagamglogene autotemcel (exa-cel) gene therapy offers a potential cure for severe sickle cell disease, now available on NHS.